LY3884963 + Methylprednisolone + Optional Sirolimus + Optional Prednisone
Phase 1/2Active 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Frontotemporal Dementia
Conditions
Frontotemporal Dementia
Trial Timeline
Nov 9, 2020 → Nov 30, 2029
NCT ID
NCT04408625About LY3884963 + Methylprednisolone + Optional Sirolimus + Optional Prednisone
LY3884963 + Methylprednisolone + Optional Sirolimus + Optional Prednisone is a phase 1/2 stage product being developed by Eli Lilly for Frontotemporal Dementia. The current trial status is active. This product is registered under clinical trial identifier NCT04408625. Target conditions include Frontotemporal Dementia.
What happened to similar drugs?
0 of 2 similar drugs in Frontotemporal Dementia were approved
Approved (0) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
9
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04408625 | Phase 1/2 | Active |
Competing Products
7 competing products in Frontotemporal Dementia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AL001 + Placebo + Open label - AL001 | Alector | Phase 3 | 22 |
| AL001 | Alector | Phase 2 | 25 |
| galantamine hydrobromide | Johnson & Johnson | Phase 2 | 35 |
| memantine hydrochloride | Lundbeck | Phase 3 | 37 |
| Syntocinon | Brain Biotech | Phase 2 | 21 |
| DNL593 + Placebo | Denali Therapeutics | Phase 1/2 | 30 |
| PBFT02 | Passage Bio | Phase 1/2 | 29 |